ENZN — Viskase Holdings, Inc.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 727510 ·
Last close
$4.71
Market Cap
$67.50M
52W High
$4.95
52W Low
$4.00
ADV30
1,301
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 86,537,000 | 9,000,000 | -3,970,000 | -6,689,000 | 428,874,000 | 28,619,000 | 238,190,000 |
| Dec 2025 | 81,727,000 | 4,850,000 | -9,879,000 | -18,679,000 | 402,142,000 | 9,217,000 | 257,782,000 |
| Sep 2025 | 91,162,000 | 5,865,000 | -8,055,000 | -12,984,000 | 399,836,000 | 7,692,000 | 250,521,000 |
| Jun 2025 | 97,279,000 | 11,634,000 | -1,683,000 | -20,246,000 | 414,241,000 | 8,912,000 | 254,420,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$19,784,000
Inventory
$108,022,000
Receivables
$73,211,000
ST Investments
—
EBIT TTM
$-3,068,000
Pretax Income TTM
$-5,905,000
Interest Exp TTM
$2,837,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$356,704,992
EBITDA
$-6,137,000
Free Cash Flow
$-8,197,000
Enterprise Value
$184,879,136
Total Cash
$28,619,000
Total Debt
$151,955,008
Shares Out
14,331,620
Trailing EPS
$-8.26
Book Value
$13.41
ROE
-32.3%
ROA
-3.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 364,356,000 | -17,268,000 | -65,494,000 | 402,142,000 | 257,782,000 | — | 12,998,000 |
| Dec 2024 | 403,775,000 | 17,800,000 | -5,360,000 | — | — | — | 3,369,000 |
| Dec 2023 | 445,984,000 | 39,721,000 | 13,506,000 | — | — | — | 44,165,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRDF | Cardiff Oncology, Inc. | $66.90M | $0.86 | — |
| LONA | LeonaBio, Inc. | $66.32M | $7.06 | — |
| GNTA | Genenta Science S.p.A. | $71.84M | $1.49 | — |
| IMA | ImageneBio, Inc. | $63.01M | $5.54 | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $74.47M | $5.36 | — |
News headlines (Yahoo Finance, 1h cache)
Enzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
2026-03-25 12:45 · Yahoo
Enzon Announces Reverse Stock Split
2026-03-24 12:45 · Yahoo
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
2026-03-19 20:30 · Yahoo
Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger
2026-01-30 22:15 · Yahoo
Enzon and Viskase Announce Amendment to Merger Agreement
2025-10-24 20:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.